Bluejay Diagnostics, Inc. (BJDX) Research
Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.
Market snapshot
- Symbol
- BJDX
- Price
- $4.46
- Day change
- +0.45%
- Market cap
- $2.0M
- P/E ratio
- -0.29x
- 52-week range
- 1.623-16.68
- Sector
- Healthcare
- Industry
- Medical - Devices
- Next earnings
- in 2 months
Recent news
- What's Going On With Bluejay Diagnostics Shares On Wednesday?
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) shares are trading lower on Wednesday. On Tuesday, the company disclosed a private placement that aims to raise up to $23.6 million.
Peer companies
Recent insider activity
- Wurth Douglas Clark — P-Purchase (12500 shares) on 2026-03-14
- Dey Indranil — P-Purchase (12500 shares) on 2026-03-14
- CHASE DONALD R — P-Purchase (12500 shares) on 2026-03-14
- ZEIDMAN FRED S — P-Purchase (12500 shares) on 2026-03-14
- Dey Svetlana — P-Purchase (12500 shares) on 2026-03-14
Open Bluejay Diagnostics, Inc. (BJDX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.